Table 2.
Proportion of NOR-DMARD registry patients stopping therapy over 24 months
| Reason, n (%) | MTX monotherapy (n = 714) | bDMARD monotherapy (n = 396) | bDMARDs + MTX (n = 1460) | bDMARDs + other csDMARDs (n = 208) | All patients (n=2778) |
|---|---|---|---|---|---|
| Lack of efficacy | 98 (13.7) | 82 (20.7) | 284 (19.5) | 46 (22.1) | 510 (18.4) |
| Adverse events | 59 (8.3) | 63 (15.9) | 133 (9.1) | 10 (4.8) | 265 (9.5) |
| Lack of efficacy and adverse events | 8 (1.1) | 7 (1.8) | 25 (1.7) | 4 (1.9) | 44 (1.6) |
| Patient’s decision | 6 (0.8) | 8 (2.0) | 24 (1.6) | 4 (1.9) | 42 (1.5) |
| Lost to follow-up | 14 (2.0) | 2 (0.5) | 13 (0.9) | 0 (0.0) | 29 (1.0) |
| Remission | 7 (1.0) | 3 (0.8) | 7 (0.5) | 2 (1.0) | 19 (0.7) |
| Other (death, pregnancy, unknown, other reasons) | 79 (11.1) | 44 (11.1) | 122 (8.4) | 32 (15.4) | 277 (10.0) |
| Total rate | 271 (38.0) | 209 (52.8) | 608 (41.6) | 98 (47.1) | 1186 (42.7) |
bDMARD: biologic DMARD; csDMARDs: conventional synthetic DMARDs; NOR-DMARD: Norwegian DMARD.